Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 1/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.30 |
| ▸ | BTK | Q06187 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15638690 | 0.78 | MAPK14 (0.47) | TGFBR1ROCK1ROCK2MAPK14ADORA2A | |
| SCHEMBL15638792 | 0.73 | TGFBR1 (0.46) | TGFBR1ROCK1ROCK2MAPK14 | |
| SCHEMBL15639974 | 0.72 | TRPA1 (0.52) | TGFBR1ROCK2MAPK14 | |
| SCHEMBL15639153 | 0.67 | ROCK2 (0.42) | ROCK1ROCK2MAPK14ADORA2ABTK | |
| SCHEMBL30117459 | 0.66 | TGFBR1 (0.52) | TGFBR1 | |
| SCHEMBL15638153 | 0.66 | TGFBR1 (0.52) | TGFBR1 | |
| SCHEMBL15639401 | 0.66 | ROCK1 (0.53) | TGFBR1ROCK1ROCK2MAPK14ADORA2A | |
| SCHEMBL15639817 | 0.65 | TGFBR1 (0.52) | PTK2TGFBR1ROCK1ROCK2 | |
| SCHEMBL16473226 | 0.65 | TRPA1 (0.54) | TGFBR1ROCK2MAPK14 | |
| SCHEMBL15638051 | 0.64 | DYRK1A (0.50) | TGFBR1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10858335-B2 | 2,3-Disubstituted pyridine compounds as TGF-β inhibitors and methods of use | RIGEL PHARMACEUTICALS, INC. (US) | 2020-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10858335-B2 | 2,3-Disubstituted pyridine compounds as TGF-β inhibitors and methods of use | SMAD3, TGFBR1, TGFBR2 | PTK2 186/4885TGFBR1 2/4885ROCK1 306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.